Stockscreener 앱 받기
80.00
1.45%
1.14
시간 외 거래:
81.58
1.58
+1.97%
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
Wells Fargo & Company Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Wells Fargo Initiates Dianthus Therapeutics at Overweight - marketscreener.com
Wells Fargo reiterates Dianthus Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP - Insider Monkey
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit - AOL.com
Biotech shares soar by 288% following a major funding round, with an early investor disclosing a $14 million cash-out - Bitget
Dianthus Therapeutics, Inc. (DNTH) stock jumps 12.0%: Will it continue to soar? - MSN
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update - MSN
Top 5 Boring Stocks That Make Money - Insider Monkey
[Form 4] Dianthus Therapeutics, Inc. /DE/ Insider Trading Activity - Stock Titan
Guggenheim reiterates buy rating for Dianthus Therapeutics (DNTH) - MSN
William Blair Maintains Outperform on Dianthus Therapeutics (DNTH) March 2026 - Meyka
Dianthus Therapeutics closes $719M public offering - Investing.com Nigeria
HighVista Strategies Boosts Stake in Dianthus Therapeutics - National Today
HighVista Strategies LLC Buys 38,364 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics Raises $719M in Upsized Offering - National Today
Dianthus Therapeutics, Inc. $DNTH is Fairmount Funds Management LLC's Largest Position - MarketBeat
Boothbay Fund Management Buys Stake in Dianthus Therapeutics - National Today
Boothbay Fund Management LLC Buys Shares of 138,963 Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (DNTH) Is Up 19.4% After Early CAPTIVATE GO Decision And $719M Raise - simplywall.st
Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm - MarketBeat
Braidwell LP Purchases Shares of 835,057 Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics announces proposed $400 million public share offering - MSN
Assessing Dianthus Therapeutics (DNTH) Valuation After Early CAPTIVATE GO Decision And Premium P/B Multiple - Sahm
Dianthus Therapeutics launches $400M stock offering - Investing.com Nigeria
Integral Health Asset Management Acquires 150,000 Shares in Dianthus Therapeutics - National Today
Integral Health Asset Management LLC Buys New Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus therapeutics CAO sells shares for $3.56 million - Investing.com Nigeria
Dianthus Therapeutics EVP Sells $2.76M in Stock - National Today
Dianthus therapeutics CAO sells shares for $3.56 million By Investing.com - Investing.com Australia
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells 43,682 Shares of Stock - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) CEO Sells 122,918 Shares - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,756,468.40 in Stock - MarketBeat
Dianthus therapeutics CEO Garcia sells $10m in shares - Investing.com
Dianthus Therapeutics EVP Randhawa sells shares for $2.76 million By Investing.com - Investing.com Nigeria
Dianthus Therapeutics EVP Randhawa sells shares for $2.76 million - Investing.com
Dianthus Therapeutics Executives Sell Off Significant Shares - TradingView
Dianthus Therapeutics closes $719M public offering By Investing.com - Investing.com Australia
Dianthus Therapeutics Announces Major Public Equity Offering - The Globe and Mail
Dianthus Therapeutics stock surges 25% on positive trial data - Investing.com Nigeria
Dianthus (DNTH) CAO cashes out 43,682 shares after option exercises - Stock Titan
Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision - Yahoo Finance
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Bitget
Biotech Dianthus raises $719M to push autoimmune disease drugs - Stock Titan
Dianthus Therapeutics Launches $81-Per-Share Offering; Net Proceeds Expected at $673.5 Million - TradingView
Dianthus (NASDAQ: DNTH) raises $673.5M in stock and warrant deal - Stock Titan
Q1 EPS Estimate for Dianthus Therapeutics Reduced by Analyst - MarketBeat
Midtown drug company to sell up to $625M in stock to fund autoimmune research - Crain's New York
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits
Dianthus Therapeutics (DNTH) offers 7.31M shares, $624.9M gross - Stock Titan
Best Biotech Stocks To ConsiderMarch 11th - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Strong Trading Volume After Analyst Upgrade - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):